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Abstract
Background: Older people are vulnerable to sustained high levels of psychosocial distress following a crime. A
cognitive behavioural therapy (CBT)-informed psychological therapy, the Victim Improvement Package (VIP) may aid
recovery. The VIP trial aims to test the clinical and cost-effectiveness of the VIP for alleviating depressive and anxiety
symptoms in older victims of crime.
Methods/design: People aged 65 years or more who report being a victim of crime will be screened by
Metropolitan Police Service Safer Neighbourhood Teams within a month of the crime for distress using the Patient
Health Questionnaire-2 and the Generalised Anxiety Disorder-2. Those who screen positive will be signposted to
their GP for assistance, and re-screened at 3 months. Participants who screen positive for depression and/or anxiety
at re-screening are randomised to a CBT informed VIP added to treatment as usual (TAU) compared to TAU alone.
The intervention consists of 10 individual 1-h sessions, delivered weekly by therapists from the mental health
charity Mind.
The primary outcome measure is the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI), used
as a composite measure, assessed at 6 months after the crime (post therapy) with a 9-month post-crime follow-up.
Secondary outcome measures include the EQ-5D, and a modified Client Service Receipt Inventory. A total of 226
participants will be randomised VIP:TAU with a ratio 1:1, in order to detect a standardised difference of at least 0.5
between groups, using a mixed-effects linear-regression model with 90% power and a 5% significance level
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(adjusting for therapist clustering and potential drop-out).
A cost-effectiveness analysis will incorporate intervention costs to compare overall health care costs and quality of
life years between treatment arms. An embedded study will examine the impact of past trauma and engagement
in safety behaviours and distress on the main outcomes.
Discussion: This trial should provide data on the clinical and cost-effectiveness of a CBT-informed psychological
therapy for older victims of crime with anxiety and/or depressive symptoms and should demonstrate a model of
integrated cross-agency working. Our findings should provide evidence for policy-makers, commissioners and
clinicians responding to the needs of older victims of crime.
Trial registration: International Standard Randomised Controlled Trials Number, ID: ISRCTN16929670. Registered on
3 August 2016.
Keywords: Older victims, Crime, Anxiety, Depression, CBT
Background
Anyone can be a victim of crime. Its behavioural and
psychological effects on quality of life can be severe [1].
Older people may be particularly vulnerable to the ef-
fects of crime because of concurrent life events, such as
family bereavements, diminishing support networks, in-
creasing physical frailty or financial difficulties [2–5].
Consequently, older people may feel more isolated, more
vulnerable, and require additional support following a
crime [5].
Our society continues to age, with people aged 85
years or over estimated to reach 3.2 million in the UK
by 2033 [6]. From the limited data on the impact of
crime in older people, there appear to be increases in
psychological distress, social care needs and mortality.
Older victims of crime have significant levels of depres-
sion and anxiety [4, 7, 8] and are at increased risk of
needing placement in a care home [9], or death [10],
compared to their peers who have not experienced a
crime. Psychological morbidity also compounds age-
associated ill-health and disability, leading to higher use
of social and health care services [11].
Currently, 95% of depressed older people receive no
specific treatment, with only 5% being referred to mental
health services compared to 50% of younger adults, and
only 3.7% of referrals for psychological therapies being
for older people [12]. Failure to treat depression and
anxiety in older people often leads to chronicity of their
symptoms for months or years [13].
There is scant research regarding specific interventions
for older people who have been victims of crime. One
small study of a video-based intervention for those with
anxiety or depressive symptoms showed no significant
benefit [14]. Our National Institute for Health Research-
funded study ‘Helping Aged Victims of Crime’ (HAVoC)
[8], which assessed the impact of crime and its manage-
ment in older people, confirms its significance as a pub-
lic health issue: 3 months after a crime, 65% of victims
felt that it had affected their daily life and 27% were
psychologically distressed, with just under a half meeting
Diagnostic and Statistical Manual of Mental Disorders
4th Edition (DSM-IV) criteria for a psychiatric disorder
attributed to the crime. Findings from the HAVoC study
[8] suggest that our specially tailored cognitive behav-
ioural therapy (CBT)-informed psychological therapy,
the Victim Improvement Package (VIP) may benefit
people with depressive- and anxiety-related symptoms.
Findings from the HaVoC study informed the present,
fully powered randomised controlled trial (RCT) to test
the clinical and cost-effectiveness of the addition of a
psychological therapy (the VIP) to usual care, compared
to usual care alone.
Objectives
The objectives of this study are as follows:
1. Primary objective: to determine whether older
victims with depression and/or anxiety present 3
months after a crime benefit from a VIP to reduce
continued severity of symptoms 6 months post
crime
Secondary objectives were:
2. Symptom severity: as above, but measured at 9
months post crime (follow-up)
3. Quality of life: to determine whether older victims
benefit from a VIP in terms of improving quality of
life at 6 and 9 months post crime
4. Economic: to determine the cost-effectiveness of the
VIP
5. Health inequalities: to explore the impact of the
VIP on health inequalities
6. Signposting: to explore the effectiveness of
signposting to primary care
7. Service delivery: to demonstrate an effective model
for identifying, referring and treating older victims
of crime suffering from depression and/or anxiety
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Methods/design
Study design
This trial will use mixed quantitative and qualitative
methods as recommended by the Medical Research
Council’s guidelines on for complex interventions [15].
The main trial is a parallel-group, single-blind, individu-
ally randomised controlled trial comparing treatment as
usual (TAU) against TAU plus up to 10 sessions of a
VIP. Randomisation will be stratified by anxiety alone or
depression with or without anxiety.
Ethical approval
This trial has been approved by the University College
London (UCL) Ethics Committee (project No. 6960/
001), and is sponsored by UCL. The trial will be con-
ducted in compliance to the Declaration of Helsinki. In-
formed written consent will be obtained from all
participants.
Population
The study population consists of victims aged 65 years
or more with symptoms of anxiety and/or depression at-
tributed to being the victim of a crime (specific crimes
included are outlined in the entry criteria below).
Location
Participants will be recruited from nine London bor-
oughs: Hackney, Tower Hamlets, Camden, Islington,
Barnet, Havering, Haringey, Newham and Enfield. These
areas were selected for demographic diversity (ethnicity,
social economic status) and because of the availability of
local psychological services, provided by the mental
health charity Mind.
Recruitment methods and procedures
Recruitment into this RCT follows a three-step proced-
ure, comprising: (1) screening; (2) re-screening; and (3)
the RCT. These three steps are outlined below:
Step 1
Screening. Any person aged 65 years or more, recorded
as a victim of crime (excluding domestic and sexual
crimes) from one of nine London boroughs will be iden-
tified from a computer search on the Metropolitan Po-
lice Service (MPS) database. Identified victims will be
contacted by a police administrator to arrange a visit (ei-
ther a police community support officer or a police con-
stable), from one of the MPS Safer Neighbourhood
Teams (SNTs) within a month of the crime.
A pre-populated proforma completed by a central ad-
ministrator will be forwarded to a police officer who
then visits to explain the trial to victims. Informed con-
sent to participate will be sought by the visiting officer.
If the person agrees, the officer will collect additional
demographic information and details about the crime as
well as screening the victim for depressive and anxiety
symptoms using abbreviated forms of the Patient Health
Questionnaire (PHQ-2 [16]) and Generalised Anxiety
Disorder Scale (GAD-2 [17]), respectively (see Table 1).
Victims who score 3 or more on the PHQ-2 and/or 2 or
more on the GAD-2 are considered screen-positive;
scores below these cut-offs on both of these measures
are case-negative. The police will then signpost the
screen-positive participants to their general practitioner
(GP), providing an accompanying letter that states that
the person appears to be experiencing significant dis-
tress, recommending that the GP should manage them
as they see fit. Those who are screen-negative are pro-
vided with information about the impact of crime and
advised to see their GP if they develop symptoms of anx-
iety or depression.
The trial will start with SNTs screening all suitable
older victims for distress. However, as police resources
are constrained, once we have established that SNTs can
screen both positive and negative older victims, proce-
dures will be adapted to screen older victims over the
phone and only for SNTs to visit those who are screen-
positive or deemed vulnerable. This will ensure that po-
lice resources are targeted at distressed older victims
only.
In addition to the above a subset of screen-positive
and screen-negative victims from steps 1 and 2, are in-
vited to take part in qualitative interviews. Details of
these are outlined in the ‘Qualitative research’ section
below.
Step 2
Re-screening. Screen-positive victims from step 1 are
re-screened 3 months after the crime over the phone for
continued symptoms of depression (≥ 3 on PHQ-2) and/
or anxiety (≥ 2 on GAD-2). Eligibility criteria (outlined
below) are assessed. A home visit by a trial researcher
further assesses participants to ensure that they satisfy
all the entry criteria for the RCT (step 3).
Step 3
RCT. Those satisfying entry criteria are given a copy of
the participant information sheet for the RCT, and given
at least 48 h to consider and discuss its contents prior to
any request for informed consent to participate in the
trial.
Eligibility criteria
Inclusion criteria are:
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1. Victim of a reported crime including common
assault, actual bodily harm, grievous bodily harm,
harassment, racist crime, homophobic crime, false
representation (deception), burglary, distraction
burglary, criminal damage to property, theft
including pick-pocketing and snatch.
2. Age 65 years or older
3. Symptoms of depression (indicated by a score of 3 or
more on the PHQ-2 [16]) and/or symptoms of anxiety
(indicated by a score of 2 or more on the GAD-2 [17])
Exclusion criteria are:
1. Having ever been diagnosed with schizophrenia or
bipolar disorder (assessed with yes/no questions).
These diagnoses are not targeted by the VIP
intervention and could affect outcome
2. A Mini-International Neuropsychiatric Interview
(MINI [18]) diagnosis of alcohol dependency
3. Receipt of CBT in the last 6 months
4. Inability to participate in CBT because of
insufficient proficiency in the English language
5. Significant cognitive impairment, indicated by a six-
item Cognitive Impairment Test [19] score of 10 or
more
6. High suicide risk determined by the MINI
Risk management
For people deemed to be a high suicide risk on the
MINI, our protocol ensures safety by notifying the par-
ticipant’s GP, a relative or, in rare cases, the police so
that a further assessment may be sought about risk. The
researcher will remain with the participant until add-
itional help is available. A discussion with the chief in-
vestigator also takes place to determine whether they are
suitable for the trial.
Randomisation
Participants who consent to enter the RCT and
complete baseline measures (step 3 of the study, 3
months post crime) are randomised to one of two condi-
tions: TAU or TAU plus the VIP. Randomisation is con-
ducted by the trial administrator using a web-based
randomisation service, Sealed Envelope, provided by
PRIMENT Clinical Trials Unit, an independent United
Kingdom Clinical Research Collaboration registered clin-
ical trials unit. This randomisation system has been pre-
populated with a randomised list provided by an inde-
pendent PRIMENT statistician and uses random per-
muted blocks of variable size to stratify participants by
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram showing trial time points
Summary of main measures (all with
reference to post crime)
Post-crime eligibility check Enrolment Post allocation Closeout
0 (post crime) 3 months Baseline
3 months
Post intervention
6 months
Follow-up
9months
Enrolment:
Post-crime eligibility screen X
Baseline eligibility screen X
Informed consent X
Allocation X
Interventions:
Victim Improvement Package X
Treatment as usual X
Assessments:
BDI-II X X X
BAI X X X
MINI (caseness)/specific anxiety disorder X X
EQ5-D X X X
CSRI X X X
Childhood Trauma Questionnaire X
Safety Behaviour Questionnaire X X X
Satisfaction with VIP X
Expectation of therapy X
Blindness assessment by research assistant X X
Attrition and reason X X
Fidelity: adherence and CTS-R X
BAI Beck Anxiety Inventory, BDI-II Beck Depression Inventory-II, CSRI Client Service Receipt Inventory, CTS-R Cognitive Therapy Scale-Revised, EQ-5D EuroQol 5
dimensions health survey, MINI Mini-International Neuropsychiatric Interview, VIP Victim Improvement Package
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their primary diagnosis (anxiety alone or depression with
or without anxiety).
Attempts will be made to ensure that all researchers
collecting outcome measures are kept blind to the group
allocation.
Descriptions of the interventions
The Victim Improvement Package (VIP)
Therapist background and training Therapists from a
major national mental health charity (Mind), previously
trained in CBT techniques and with at least 2 years’ ex-
perience in delivering CBT will be the main target for
therapist selection, being chosen to be at a standard ac-
creditable by the British Association of Behavioural and
Cognitive Psychotherapies (BABCP). However, we will be
constrained by the availability of therapists and will adapt
a pragmatic approach, using therapists who are experi-
enced in psychological approaches and have undertaken
training in CBT. All therapists will be given a full day of
training on how to apply their existing skill set to the VIP
intervention. They will be taken through the VIP manual
step by step and also asked to participate in role plays of
various scenarios typical of older victims of crime.
Delivery of therapy Up to 10 manualised [20] individ-
ual sessions of CBT especially modified for older crime
victims will be delivered over 3 months, in community-
based Mind facilities. If the victim has a preference to be
treated in their own home; for example, due to physical
disability or if they fear leaving the house after the crime,
they can, at the discretion of the Mind therapist, receive
the therapy in their home. In this instance the local
Mind centre’s lone-working policy will be adhered to at
all times while providing home therapy.
Content of therapy Full details of the VIP manual have
been published and are available from the chief investi-
gator [20]. The VIP, tailored to the main presenting
symptoms and used flexibly, will cover: Session 1: a nar-
rative of the crime, underlying beliefs, behaviours and
how these have changed; Session 2: psycho-education
about crime and an introduction to CBT; Sessions 3–8:
mood diaries to identify unhelpful thinking and behav-
iours; guided discovery to challenge beliefs about crime,
personal vulnerability and safety; behavioural experi-
ments to challenge unhealthy avoidance; Sessions 9–10:
relapse prevention. Therapy sessions will follow a typical
CBT model: setting an agenda, conducting therapy and
encouraging between-session homework exercises.
Treatment as usual (TAU)
Historically, all older crime victims were offered a visit
from a SNT, which is usual care for the purpose of the
trial. However, changes in resources suggest that po-
licing will shift to SNTs undertaking selected ‘cocooned’
visits to victims (burglary and those deemed vulnerable
by the MPS). Informal support may be provided by net-
works of friends and relatives, where available.
Voluntary agencies All victims are routinely provided
with information on how to contact Victim Support.
This relies on the victim proactively requesting assist-
ance, which older people do not usually appear to do
[8]. People may also self-refer to Mind. In reality, few
older people take up offers of help when contacted by
letter [8].
GP referral Concerning older people, our previous
qualitative work found that victims do not usually seek
help from their GP directly, as they do not believe that
the problem is ‘medical’. When referred to the GP with
depressive and anxiety symptoms they may not be man-
aged according to best practice as indicated in the Na-
tional Institute of Health and Care Excellence (NICE)
guidelines, especially when distress is seen as under-
standable or associated with ageing [12]. A small num-
ber may be prescribed psychotropic medication, but
many are reluctant to take these [21]. With anti-
depressant use there may be difficulties with compliance,
fears of dependence, interactions and side effects.
Psychotherapy referral A recent development in Eng-
land has been the Improving Access to Psychological
Therapies (IAPT) service where people may self-refer, or
be referred by their GP. These IAPT services use a
stepped-care model with provision for limited CBT.
CBT is recommended by NICE as an effective treatment
for anxiety and depression in people of all ages, but gen-
erally very few older people receive this [12]. We will
not exclude the possibility of participants receiving CBT
in the TAU arm for ethical reasons, but we will record
any receipt of this and account for it in the analysis.
Traumatic Stress Clinics: these rarely see older adult
victims and, as they are tertiary services, it may take
people at least a year to gain access to treatment.
Access to independent practitioners: for economic rea-
sons, older people are less likely to pursue privately fi-
nanced options.
Where the participant requests it, their GP will be in-
formed about the study and their patient’s symptoms.
We will not encourage referral for CBT or starting or in-
creasing psychotropic medication during the trial.
Outcomes
Primary outcomes
The Beck Depression Inventory-II (BDI-II) [22] and
Beck Anxiety Inventory (BAI) [23] are used for those
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diagnosed with depression and anxiety, respectively, to
measure participants’ progress. These two scales will be
adjusted to enable us to compare improvements in de-
pression or anxiety using ‘standardisation’. For each out-
come (BDI-II and BAI), standardisation entails
subtracting the corresponding sample mean and dividing
by the corresponding sample standard deviation, to pro-
duce a composite outcome for all participants (whether
anxious or depressed). Both the BDI-II and BAI are self-
reported scales with 21 items each having four possible
answer choices. They have good reliability and validity
for measuring severity of depression and anxiety, re-
spectively. The BDI-II has the advantage over other
scales because it includes a significant number of
cognitive-affective as well as somatic dimensions. The
BAI is composed of cognitive and somatic elements.
Secondary outcomes
Diagnostic category The Mini-International Neuro-
psychiatric Interview (MINI) [18] is used to assist diagnos-
tically, as it generates a Diagnostic and Statistical Manual
of Mental Disorders, 4th edition (DSM-IV) diagnosis of at
least one of the following (we have included the equivalent
International Classification of Diseases 10th edition (ICD-
10) codes in brackets): depression with or without anxiety,
DSM 296.2x, 296.3x, (ICD-10 F32.x); panic disorder with-
out agoraphobia 300.01 (ICD-10 F41.0) or with agorapho-
bia 300.21 (ICD-10 F41.0); generalised anxiety disorder
DSM-IV 300.02 (ICD-10 F41.1); agoraphobia without his-
tory of panic disorder DSM-IV 300.22, (ICD-10 F41.1). Al-
though the MINI does not generate a diagnosis of specific
anxiety disorder DSM-IV 300.09 (ICD-10 F41.8), which is
relevant to our target population, this diagnostic group
will also be included in the study if participants experience
significant anxiety attributable to the crime.
The EuroQol 5 dimensions health survey (EQ5-D; Ra-
bin 2001) is a five-item generic utility measure of quality
of life. It has been selected because: (1) It is brief, easy to
use, and minimises attrition; (2) It compares favourably
with other measures [24, 25]; (3) It has been used exten-
sively with older people [26]; (4) We have used it with
depressed older people [27, 28] and older victims of
crime [8]; and (5) It is recommended by NICE for health
economics [29], including trials with older people [30].
The Client Service Receipt Inventory: (CSRI; Curtis
2008) a modified version of the CSRI, developed for the
present study, will be used to collect data on service use
to inform the health economic analysis.
Generalised Anxiety Disorder Assessment (GAD-7) and
Patient Health Questionnaire (PHQ-9). The PHQ-9 and
the GAD-7 are valid measures of depression and anxiety,
respectively [31, 32], which are widely used in primary
care settings.
Other measures
Childhood Trauma Questionnaire
The Childhood Trauma Questionnaire Short Form
(CTQ-SF [33];) is a 28-item self-report screening tool
that can be used in both adults and adolescents to detect
quickly five types of childhood maltreatment: physical,
emotional and sexual abuse, and physical and emotional
neglect. The CTQ-SF has been selected because it is the
most commonly used measure to assess multiple mal-
treatment types [34] and studies support its reliability,
validity and factor structure [34, 35]. The measure has
also been used in studies with older adults (e.g. [36]).
A measure of safety behaviours
Safety behaviours (also called safety-seeking behaviours)
are counterproductive and dysfunctional overt or covert
actions intended to prevent, escape from, or reduce the
severity or risk of a potentially threatening outcome [37,
38]. A measure is being developed as part of the VIP
trial to collect data on safety behaviours in older crime
victims. Participants are prompted to provide their own
examples of excessive checking, reassurance-seeking, ru-
mination, avoidance, compulsions, hypervigilance or any
other behavioural changes. They are then asked to rate
on a 7-point Likert scale how frequently they engage in
these behaviours and how much this has changed since
the crime happened.
Measures of sources of bias during the course of the trial
At baseline (3 months post crime)
1. Prescribed anti-depressants and/or anxiolytics and/
or hypnotics: participants are asked if they are
taking any medication to help with mood,
depression, anxiety or sleep. They are also asked the
name, dose and length of prescription. Doses will be
standardised against fluoxetine/diazepam,
respectively, to see whether they are equivalent in
both trial arms
2. Other psychological therapies reported by
participants
3. Expectations at baseline: participants will be asked
to predict the degree of expected improvement, or
not, on a Likert scale ranging from 0 to 10
4. Treatment preference: participants’ treatment group
preference (VIP group/TAU group/no preference)
will be recorded at baseline
5. Cancelled/missed therapy sessions
Post therapy (6months)
1. Measures of attrition and engagement with therapy:
during the course of the study we expect a few
participant deaths, which are likely to be random.
Additionally, we will record change of residence,
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illness, geographical distance from therapy, did not
attend rates, and the reasons for not doing so
2. Assessment of ‘blindness’ by rater. At the primary
endpoint of 6 months, once the BDI-II and BAI
have been rated, the researcher will be asked to
guess the group allocation (TAU or VIP or not
sure)
3. Changes in prescribed psychotropic medication: anti-
depressant or anxiolytic/hypnotic medication
4. Other psychological treatments received. This may
include seeing a counsellor, psychotherapist or
victim support counsellor and can include both
statutory and privately funded provision
5. Measures of satisfaction with treatment by rating on
a 5-point scale (not at all to very much) whether
the VIP was perceived as useful
6. Reason for missing follow-up (e.g. withdrew, died,
etc..
Timing of enrolment, interventions and measures
The timing of enrolment, allocation, collection of mea-
sures and study closeout, is summarised in the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) diagram in Table 1.
Assessment of therapists’ competence and adherence to VIP
manual
We encourage all therapists to digitally record their
therapy sessions and a random sample of 1 in 10 record-
ings will be selected for quality control for competence
of delivery of the therapy and adherence to the manual.
Therapists’ competence Treatment quality will be rated
by an accredited member of the British Association of
Behavioural and Cognitive Psychotherapies expert in the
field using the Cognitive Therapy Scale-Revised [39].
Each item is rated from 0 to 6 on a visual analogue scale,
ranging from incompetent through to novice, advanced
beginner, competent, proficient and expert. The total
score ranges between 0 and 72. Therapists would be ex-
pected to achieve a minimum score of 36.
Adherence to the VIP manual The use and the devel-
opment of a Therapy Components Checklist (TCC)
arose from previous work [27, 40] which was further de-
veloped in the HAVoC study [8]. We identified what we
considered to be 26 core elements required in the deliv-
ery of the VIP. These core elements were operationalised
in the treatment manual. Central to the components
checklist, we wanted to ensure that the therapists ad-
hered to the range of CBT procedures (i.e. they used a
combination of cognitive, behavioural and cognitive-
behavioural techniques, as well as specific issues related
to our CBT intervention for victims of crime). The
therapists will be asked to list the components of therapy
that they have covered at the end of each therapy ses-
sion. We will describe the components reported,
requesting the independent assessor responsible for rat-
ing therapists’ competence to complete the TCC for the
rated session and compare the therapists’ self-report
with their assessors report.
Therapist supervision All therapists will be asked to
phone at least once a month to the group supervision
taking place twice monthly. They will be asked to
present their therapeutic interventions that worked well
as well as identifying problem areas. They will also be
able to contact the chief investigator by phone, or by
email with a response within two working days, to dis-
cuss any major therapeutic difficulties.
Data entry and storage
Outcome data will be collected directly onto paper
forms by researchers employed on the VIP trial. Each
paper form will then be hand-delivered to the main trial
office by the trial researcher. This data will then be en-
tered onto the secure online Sealed Envelope database
by a member of the trial team (either a trial researcher
or trial administrator). A portion (10%) of all entered
data will be checked against the original paper form for
accuracy. At the end of the trial after database lock, the
trial dataset will be downloaded from Sealed Envelope
by the trial statisticians.
Trial monitoring
The trials Data Monitoring Committee comprises three
independent members including an expert in clinical tri-
als methodology and medical statistics, an expert in
mental health, and an expert in old-age psychiatry. This
Data Monitoring Committee will meet at least once a
year throughout the running of the trial. A Trial Steering
Committee will also meet once a year. The Trial Man-
agement Group, consisting of grant applicants, public
representatives, and members of the clinical trials unit
PRIMENT, will meet approximately every 3 months
throughout the running of the trial. Both the Trial Steer-
ing Committee and the Data Monitoring Committee
contain members who are independent of the trial, and
will be able to hold closed sessions without trial mem-
bers present to independently monitor the trial and
make any necessary decisions on the running of the trial.
As no harm to participants is regarded as likely from
CBT, the trial does not have specific interim analysis or
stopping guidelines. The Data Monitoring Committee
and Trial Steering Committee will have the usual power
to stop the trial if they deem this necessary, as outlined
in the National Institute for Health Research guidelines
for trial committees.
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Statistics
Power Efficacy analysis will use changes from baseline
to the end of the intervention period (6 months post
crime) in a standardised combination of BAI and BDI-II
scores. For standardisation, the corresponding sample
mean (BAI or BDI-II) will be subtracted from the BAI or
BDI-II measurement and then the resulting measure di-
vided by the corresponding sample standard deviation
(BAI or BDI-II). This will yield a standardised outcome
measure to be modelled for all trial participants
(whether anxious or depressed, with or without anxiety).
Although there is little evidence as to what constitutes a
clinically meaningful difference [41], consensus between
experts in the field suggest that a change of 0.5 of a
standard deviation, 3 or more on the BDI, is considered
a NICE-approved clinically important change [42]. It is
feasible to detect a (‘true’) average difference of at least
0.5 on the standardised joint scale with 90% power and a
5% significance level using a total sample size (N) of 168,
with participants randomised VIP:TAU with a ratio 1:1.
Applying an overall ‘cluster-adjustment’ for therapist ef-
fects, assuming a cluster-size of 8 intra-class correlation
coefficient (ICC) of = 0.02 and 15% allowance for drop-
out, increases this to N = 226. Using data from the pilot
study, the ‘target’ standardised difference of 0.5 implies
changes in both BAI and BDI-II of about 4 and this is
valuable clinically, given the scales show that for moder-
ate levels of symptoms the scores range from 20 to 28
and 16–25 for anxiety and depressive symptoms,
respectively.
Clinical-effectiveness analysis We will follow a pre-
specified plan for statistical analysis and reporting which
will be finalised before database lock, and in adherence
with Consolidated Standards of Reporting Trials (CON-
SORT) guidelines.
The primary analysis will be based on available data
and conducted according to the intention-to-treat
principle. The mean difference in the primary outcome
in the VIP group compared to the TAU group at this
time point will be estimated from a mixed-effects linear-
regression model with standardised BAI/BDI-II score at
6 months post crime as the response variable, and with
study arm, centre and baseline standardised BAI/BDI-II
score as explanatory variables. The model will account
for clustering by Mind therapist in the VIP arm using a
therapist-level random effect and a patient-level random
effect to account for repeated measures within patients.
Participants will be classified as having either ‘anx-
iety’ (alone) or ‘depression’ (with or without anxiety)
and randomisation will be stratified by this primary
diagnosis using separate analyses, comparing TAU plus
VIP vs TAU.
The primary outcome for participants in the depres-
sion stratum is BDI-II score whereas the primary out-
come for participants in the anxiety only stratum is BAI
score. A combined primary outcome for both strata will
be created in the following manner:
 BDI-II scores will be standardised by the mean and
standard deviation of BDI- II score at baseline of all
participants in the depression stratum irrespective of
allocation
 BAI scores will be standardised by the mean and
standard deviation of BAI score at baseline of all
participants in the anxiety-only stratum irrespective
of allocation
 The standardised versions of BDI-II scores from the
depression stratum and BAI scores from the
anxiety-only stratum will then be combined into a
single variable to form the primary outcome meas-
ure, used in the linear mixed-effects regression
model
Supportive analyses Bias due to missing data will be
investigated by comparing the baseline characteristics
of participants with and without missing values. De-
pending on the quantity of missing values, the predic-
tors of missingness will be identified. We will then
perform a sensitivity analysis by including any predic-
tors of missingness as explanatory variables in the pri-
mary outcome model.
If appropriate, we will also perform a multiple im-
putation analysis [43] in which we will construct a
model to impute missing BDI-II/BAI post intervention
(6 months post crime) using appropriate explanatory
variables. To account for potential differential attrition
between socio-economic groups, Lower Layer Super
Output Area (LSOA) data (an indicator of relative
deprivation) will be part of the predictor in the mul-
tiple imputation model. We will also consider baseline
BDI-II/BAI score, participant demographics recorded
at baseline, and any other variables thought to be re-
lated to missingness.
Exploratory analyses: will be carried out to describe
how a limited number of pre-specified characteristics of
participants may modify treatment effects. These will in-
clude patient preferences, relative levels of deprivation
(LSOA data) and non-compliance with treatment: the
latter being addressed using compliers’ average causal ef-
fects (CACE) analysis.
Secondary outcome variables Analyses of secondary
outcomes will be performed using models analogous to
those described in relation to the primary outcome.
Continuous outcomes will be analysed using mixed-
effects linear-regression models. Binary outcomes will be
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analysed using mixed-effects logistic regression models.
Model parameter estimates will be reported accompan-
ied by 95% confidence intervals.
Qualitative data
Semi-structured interviews will be completed with around
25 older crime victims at step 2 of the trial. The topic
guide will explore three key areas: (1) the social and cul-
tural background of the victim and how this influences
their perception of the crime; (2) safety attitudes and be-
haviours following the crime event; and (3) their experi-
ence of services and help-seeking since the crime. A
purposive sample will be sought in order to achieve a bal-
ance of socio-demographic characteristics. The interviews
will be analysed using thematic analysis [44].
Dissemination of findings
We will publish the results in the Public Health Re-
search journal in the National Institute for Health Re-
search journal library. We will also submit the study
results for publication in an appropriate peer-reviewed
journal. We will directly inform our contacts in the
Metropolitan Police Service of the findings, and we will
also write to trial participants to inform them of the
results.
Discussion
This trial is the first fully powered study, building on
our pilot HAVoC trial, to work across agencies for the
screening and treatment of depression and/or anxiety in
older victims of crime. Older people are particularly vul-
nerable to the impact of crime because of concurrent life
events; family bereavements, physical ill-health, disabil-
ity, financial difficulties [2, 3, 45]. As the proportion of
older people in the UK population rises, society is going
to be increasingly impacted by this. Older victims of
crime experience significant levels of depression and
anxiety, which in many persists for months after victim-
isation [8]. The VIP trial should provide robust evidence
about the effectiveness and cost-effectiveness of treating
depression and/or anxiety in this population.
Research implications
There are virtually no studies published about the mental
health of older victims of crime. This trial should demon-
strate the utility of a model of cross-agency working in
which the police screen older victims of crime, the univer-
sity team follow-up the victims, and the mental health
charity Mind deliver a psychological treatment.
Older victims are particularly hard to reach. Despite
significant symptoms of anxiety and depression, which
develop rapidly after a crime, existing health care and
voluntary services appear unaware of these. If feasible,
our model for screening victims, identifying distress and
referring for treatment, could be adapted to other re-
search projects in other hard-to-reach and vulnerable
victim groups, such as people with intellectual difficul-
ties, in whom mental distress may otherwise be missed.
Clinical and policy implications
The primary objective of the VIP trial is to determine
whether manualised, context-specific CBT, delivered
through the mental health charity Mind, is more clinic-
ally and cost-effective than TAU for treating anxiety and
depression in older victims of crime. Secondary objec-
tives should determine whether older people take up the
offer of signposting, and whether health professionals
act on this as part of the first step in public health pre-
vention to reduce the potential chronicity of symptoms.
The built-in cost-effectiveness analysis should also help
evaluate the indirect costs associated with the impact of
crime and whether the intervention appears to be cost-
effective, such as, for example, reducing the use of health
care or social services in this vulnerable population. The
final objective is to evaluate whether the model of cross-
agency working is successful so that it can then be rolled
out across the UK. In this model, the police identify
older victims of crime, screen them for distress and,
using a coordinator embedded in the police, refer dis-
tressed older victims for further evaluation to see
whether a CBT intervention is indicated. Delivery of
CBT could be undertaken by a variety of agencies, in-
cluding Mind, IAPT or referral to accredited CBT thera-
pists practising within a GP or community setting.
This trial should provide information on: the propor-
tion of crimes against older people compared to their
younger counterparts; the mental health impact that
crimes have on older people; the relationship between
different types of crime and mental health; the chronicity
of anxiety and depressive symptoms associated with a
crime; and the health care costs associated with crime. It
should also generate evidence to inform guidelines for
the Ministry of Justice on how the needs of older victims
may be managed.
If our findings suggest that signposting to existing ser-
vices by the police does not work as part of public health
prevention strategy, older victims could be referred dir-
ectly to mental health services for active surveillance of
symptoms, so that an intervention can be delivered if ne-
cessary. This framework could still be used nationally
and internationally to manage distressed older victims of
crime.
Trial status
This study began recruiting on 1 September 2017 and is
currently recruiting, with recruitment estimated to end
on 30 April 2021. The current trial protocol is version 8,
17 February 2018.
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